These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 10169635)

  • 41. Now there are four: Carvedilol takes its place in therapeutical line-up for heart failure.
    Phillips L
    Hosp Technol Ser; 1997 Mar; 16(3):6-7. PubMed ID: 10166705
    [No Abstract]   [Full Text] [Related]  

  • 42. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world?
    Wollert KC; Drexler H
    Circulation; 2002 Oct; 106(17):2164-6. PubMed ID: 12390940
    [No Abstract]   [Full Text] [Related]  

  • 43. Primary results of COPERNICUS, a pivotal landmark study (Carvedilol Prospective Randomised Cumulative Survival Trial).
    Cardiovasc J S Afr; 2001; 12(1):57. PubMed ID: 11474691
    [No Abstract]   [Full Text] [Related]  

  • 44. Beta-blockade in heart failure: a potential role.
    Kwasniewski R; Clem J
    S D J Med; 1997 Jan; 50(1):25-6. PubMed ID: 9029989
    [No Abstract]   [Full Text] [Related]  

  • 45. Carvedilol therapy in heart failure--I.
    Ghali JK
    J Am Coll Cardiol; 1995 Nov; 26(5):1399; author reply 1400-1. PubMed ID: 7594059
    [No Abstract]   [Full Text] [Related]  

  • 46. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.
    Stewart S; McMurray JJ; Hebborn A; Coats AJ; Packer M;
    Int J Cardiol; 2005 Apr; 100(1):143-9. PubMed ID: 15820297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program.
    Vera-Llonch M; Menzin J; Richner RE; Oster G
    Ann Pharmacother; 2001; 35(7-8):846-51. PubMed ID: 11485131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beta blocker benefits patients with advanced heart failure.
    Geriatrics; 2000 Nov; 55(11):18, 21. PubMed ID: 11086468
    [No Abstract]   [Full Text] [Related]  

  • 49. Carvedilol in class IV heart failure.
    Hoffman I
    J Am Coll Cardiol; 1999 Dec; 34(7):2149-50. PubMed ID: 10588239
    [No Abstract]   [Full Text] [Related]  

  • 50. Beta blockers for congestive heart failure.
    Gilbert EM
    Postgrad Med; 1998 Feb; 103(2):25-6. PubMed ID: 9479305
    [No Abstract]   [Full Text] [Related]  

  • 51. Expanding indications for beta-blockers in heart failure.
    Braunwald E
    N Engl J Med; 2001 May; 344(22):1711-2. PubMed ID: 11386271
    [No Abstract]   [Full Text] [Related]  

  • 52. Carvedilol in patients with chronic heart failure.
    von Olshausen K; Pop T; Berger J
    N Engl J Med; 1996 Oct; 335(17):1318-9; author reply 1319-20. PubMed ID: 8992328
    [No Abstract]   [Full Text] [Related]  

  • 53. Carvedilol and the Food and Drug Administration approval process: an introduction.
    Fisher LD; Moyé LA
    Control Clin Trials; 1999 Feb; 20(1):1-15. PubMed ID: 10027497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing.
    Fisher LD
    Control Clin Trials; 1999 Feb; 20(1):16-39. PubMed ID: 10027498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does intention-to-treat analysis answer all questions in long-term mortality trials? Considerations on the basis of the ANZ trial.
    Tillmann HC; Sharpe N; Sponer G; Wehling M
    Int J Clin Pharmacol Ther; 2001 May; 39(5):205-12. PubMed ID: 11380066
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the impact of heart failure specialist services on patient populations.
    Lyratzopoulos G; Cook GA; McElduff P; Havely D; Edwards R; Heller RF
    BMC Health Serv Res; 2004 May; 4(1):10. PubMed ID: 15157278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. End-point interpretation in clinical trials: the case for discipline.
    Moyé LA
    Control Clin Trials; 1999 Feb; 20(1):40-9; discussion 50-1. PubMed ID: 10027499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized trial of carvedilol in treatment of congestive heart failure.
    Singer RB
    J Insur Med; 1997; 29(2):82-90. PubMed ID: 10169635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure.
    Fowler MB
    Am J Cardiol; 2004 May; 93(9A):35B-9B. PubMed ID: 15144935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.